{"id":"ak104-iv-infusion-chiauranib-oral","safety":{"commonSideEffects":[{"rate":"30%","effect":"Hypertension"},{"rate":"20%","effect":"Diarrhea"},{"rate":"15%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Chiauranib is a potent and selective inhibitor of multiple receptor tyrosine kinases, including VEGFR, PDGFR, and FGFR.","oneSentence":"Tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:51:46.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05505825","phase":"PHASE1, PHASE2","title":"A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-08-26","conditions":"SCLC,Extensive Stage","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AK104 IV infusion；Chiauranib oral","genericName":"AK104 IV infusion；Chiauranib oral","companyName":"Akeso","companyId":"akeso","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyrosine kinase inhibitor Used for Non-small cell lung cancer, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}